



ASX ANNOUNCEMENT

Imugene's pig PRRS vaccine trial commences in US

18 July 2007, Sydney, Australia: Trials to evaluate Imugene's PRRS vaccine are underway at a specialist trial facility in the US. PRRS is a highly damaging disease in pigs for which there are no effective treatments.

The trials are part of Imugene's vaccine product development and follows successful previous trials of the PRRS vaccine in Australia.

Imugene managing director Dr Warwick Lamb said, "Having completed our laboratory optimisation of the vaccine, these US based trials will provide further important information about the vaccine's performance in animals. We are hoping the product optimisation will deliver higher levels of protection and possibly permit single dose administration. Our objective is to produce a vaccine administered in the drinking water or by injection."

PRRS is one of the most economically damaging pig diseases worldwide causing industry losses of up to \$1 billion each year. Initially recognised in the US in 1987 the disease spread to Europe in 1990 and subsequently across most of the rest of the world. Australia is one of three countries considered PRRS-free.

Positive results from this trial will assist Imugene's licensing negotiations with interested major international animal health companies.

The trial results are expected within 3 months.

The vaccine is based on Imugene's Porcine Adenoviral Delivery Vector that delivers selected genetic material to the pig to stimulate the immune system to protect against the PRRS virus.

ENDS

About Imugene

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the Fowl Adenoviral Vector Delivery System for poultry and the Porcine Adenoviral Vector Delivery System for pigs. Imugene has

Perth Office

Level 20, Allendale Square
77 St Georges Terrace
Perth WA 6000
Tel: +61 8 9440 2660
Fax: +61 8 9440 2699

ABN: 99 009 179 551

Sydney Office

Registered Office
Level 1, 14 – 20 Delhi Road
North Ryde NSW 2113
Tel: +61 2 9870 7330
Fax: +61 2 9888 9338

www.imugene.com

successfully licensed the first product based on the Fowl Adenoviral Vector Delivery System – the Poultry Productivity Enhancer.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market with four lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

For more information please visit the Imugene Website www.imugene.com

For more information:

Dr Warwick Lamb
Managing Director
+61 2 9870 7330

Mr Graham Dowland
Chairman
+61 8 9440 2660

Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333